The effect of peer support on fear of disease progression in patients with glioma: a protocol for systematic review and meta-analysis

• by Dandan Liang, Ruiying Jia, Qin Huang, Yanhong Pan

• July 2, 2026

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

• July 1, 2026

• 1 min

Business-in-Brief: June 2026

This month’s analytical science business news: Merck’s Bio-Techne acquisition, plus major ASMS product launches

• July 2, 2026

• 5 min

Comparative study of three treatment approaches on overall survival and treatment response in nasopharyngeal carcinoma patients: network meta-analysis of RCTs (4221 patients)

• by Jun Hu, Li Haojie

• July 2, 2026